Zobrazeno 1 - 10
of 494
pro vyhledávání: '"Edward B, Garon"'
Autor:
Ariane Lozac’hmeur, Tyler Danek, Qidi Yang, Mario G. Rosasco, John S. Welch, William Y. Go, Eric W. Ng, Armen Mardiros, David G. Maloney, Edward B. Garon, Kedar Kirtane, Diane M. Simeone, Julian R. Molina, Ameen A. Salahudeen, Michelle M. Stein, J. Randolph Hecht
Publikováno v:
npj Precision Oncology, Vol 8, Iss 1, Pp 1-9 (2024)
Abstract To enable interrogation of tumor HLA LOH as a clinical diagnostic for precision oncology, we developed and validated an assay that detects HLA LOH within the context of an FDA-approved clinical diagnostic test, Tempus xT CDx. Validation was
Externí odkaz:
https://doaj.org/article/b996755a54b34fbbaaef8cbd5b2d5b9a
Autor:
Kazumi Nishino, MD, PhD, Jin-Yuan Shih, MD, PhD, Kazuhiko Nakagawa, MD, PhD, Martin Reck, MD, PhD, Edward B. Garon, MD, Michelle Carlsen, MS, Tomoko Matsui, Carla Visseren-Grul, MD, Ernest Nadal, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 5, Iss 2, Pp 100624- (2024)
Introduction: EGFR gene mutations are drivers of NSCLC. The RELAY double-blind, placebo (PBO)-controlled phase 3 study revealed superior progression-free survival (PFS) for ramucirumab plus erlotinib (RAM + ERL) versus PBO (PBO + ERL) in patients wit
Externí odkaz:
https://doaj.org/article/5159d19b07b0438c8a46366db7862e0c
Autor:
Bin Liu, Rui Li, Edward B Garon, Steven M Dubinett, Kostyantyn Krysan, Tianhao Zhang, Aaron E Lisberg, Ramin Salehi-Rad, Raymond J Lim, Yushen Du, Linh M Tran, Stephanie L Ong, Zi Ling Huang, Camelia Dumitras, Stacy J Park, William Crosson, Bitta Kahangi, Jensen Abascal, Christopher Seet, Michael Oh, Maryam Shabihkhani, Manash Paul
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 9 (2023)
Background Despite recent advances in immunotherapy, many patients with non-small cell lung cancer (NSCLC) do not respond to immune checkpoint inhibitors (ICI). Resistance to ICI may be driven by suboptimal priming of antitumor T lymphocytes due to p
Externí odkaz:
https://doaj.org/article/bf2a559715ab4836a9534c935ea67e88
Autor:
Edward B. Garon, Carla Visseren-Grul, Maria Teresa Rizzo, Tarun Puri, Suresh Chenji, Martin Reck
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
IntroductionIn the REVEL trial, ramucirumab plus docetaxel demonstrated significant improvements in overall survival (OS), progression-free survival (PFS), and overall response rate (ORR) compared with placebo plus docetaxel for treatment of metastat
Externí odkaz:
https://doaj.org/article/b54245a672d24f66a33952de0821e809
Autor:
Clayton P. Smith, MD, Michael Xiang, MD, PhD, Stephanie M. Yoon, MD, Alan Lee, MD, Dan Ruan, PhD, Jonathan W. Goldman, MD, Amy L. Cummings, MD, Aaron Lisberg, MD, Edward B. Garon, MD, MS, Drew Moghanaki, MD, MPH
Publikováno v:
JTO Clinical and Research Reports, Vol 4, Iss 3, Pp 100468- (2023)
Introduction: Osimertinib is an effective treatment for metastatic NSCLC. Occasionally, thoracic radiation therapy (TRT) is delivered to patients receiving osimertinib to treat residual or progressing pulmonary tumors. Anecdotal reports suggest that
Externí odkaz:
https://doaj.org/article/b2b61572fb9f435fa78b46c90498509e
Autor:
Kathryn F. Mileham, Caroline Schenkel, Suanna S. Bruinooge, Janet Freeman‐Daily, Upal Basu Roy, Amy Moore, Robert A. Smith, Elizabeth Garrett‐Mayer, Lauren Rosenthal, Edward B. Garon, Bruce E. Johnson, Raymond U. Osarogiagbon, Shadia Jalal, Shamsuddin Virani, Mary Weber Redman, Gerard A. Silvestri
Publikováno v:
Cancer Medicine, Vol 11, Iss 2, Pp 530-538 (2022)
Abstract Background An ASCO taskforce comprised of representatives of oncology clinicians, the American Cancer Society National Lung Cancer Roundtable (NLCRT), LUNGevity, the GO2 Foundation for Lung Cancer, and the ROS1ders sought to: characterize U.
Externí odkaz:
https://doaj.org/article/77e04cdb969842218b3ff0a67980c00e
Autor:
Marina C. Garassino, MD, Shirish Gadgeel, MD, Silvia Novello, MD, PhD, Balazs Halmos, MD, Enriqueta Felip, MD, Giovanna Speranza, MD, Rina Hui, PhD, Edward B. Garon, MD, Hidehito Horinouchi, MD, PhD, Shunichi Sugawara, MD, PhD, Delvys Rodriguez-Abreu, MD, PhD, Martin Reck, MD, Razvan Cristescu, PhD, Deepti Aurora-Garg, PhD, Andrey Loboda, PhD, Jared Lunceford, PhD, Julie Kobie, PhD, Mark Ayers, MS, Bilal Piperdi, MD, M. Catherine Pietanza, MD, Luis Paz-Ares, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 4, Iss 1, Pp 100431- (2023)
Introduction: We evaluated tissue tumor mutational burden (tTMB) and mutations in STK11, KEAP1, and KRAS as biomarkers for outcomes with pembrolizumab plus platinum-based chemotherapy (pembrolizumab-combination) for NSCLC among patients in the phase
Externí odkaz:
https://doaj.org/article/5b31e33aa86a4148993ed9fca9e915ac
Autor:
Shuo Li, Zorawar S. Noor, Weihua Zeng, Mary L. Stackpole, Xiaohui Ni, Yonggang Zhou, Zuyang Yuan, Wing Hung Wong, Vatche G. Agopian, Steven M. Dubinett, Frank Alber, Wenyuan Li, Edward B. Garon, Xianghong Jasmine Zhou
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-14 (2021)
It is possible to call single-nucleotide variant (SNV) in cell-free DNA (cfDNA), but the accuracy of detection is often affected by low tumour cfDNA content. Here, the authors develop a method, cfSNV, and show that it can be used even for medium-cove
Externí odkaz:
https://doaj.org/article/b75641b56a1844ef8994d8abd02e0b66
Autor:
Raffit Hassan, Patrick M Forde, Edward B Garon, Steven M Dubinett, Roy S Herbst, Charu Aggarwal, Matthew D Hellmann, Sarah B Goldberg, David L Rimm, Sarah Sagorsky, Boris Sepesi, Ramaswamy Govindan, Andrea Ferris, Scott J Antonia, Fred R Hirsch, Lawrence H Schwartz, Marianne Davies, Melissa L Johnson, Shakun Malik, Daniel Morgensztern, Joel W Neal, Jyoti D Patel
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 5 (2022)
Immunotherapy has transformed lung cancer care in recent years. In addition to providing durable responses and prolonged survival outcomes for a subset of patients with heavily pretreated non-small cell lung cancer (NSCLC), immune checkpoint inhibito
Externí odkaz:
https://doaj.org/article/a7041ff7bb174ceaaf1394ae132d1c32
Autor:
Makoto Nishio, MD, PhD, Kazuto Nishio, MD, PhD, Martin Reck, MD, PhD, Edward B. Garon, MD, Fumio Imamura, MD, PhD, Tomoya Kawaguchi, PhD, Hiroyuki Yamaguchi, MD, PhD, Satoshi Ikeda, MD, PhD, Katsuya Hirano, MD, Carla Visseren-Grul, MD, Matteo Ceccarelli, PharmD, MS, Sameera R. Wijayawardana, PhD, Annamaria Zimmermann, MS, Tomoko Matsui, Sotaro Enatsu, MD, PhD, Kazuhiko Nakagawa, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 3, Iss 4, Pp 100303- (2022)
Introduction: Ramucirumab (RAM) plus erlotinib was found to have superior progression-free survival (PFS) versus placebo plus erlotinib in untreated EGFR-mutated metastatic NSCLC in the global phase 3 RELAY study. RELAY+ was an open-label, two-period
Externí odkaz:
https://doaj.org/article/2c15ffbd66fc4dc2bedf92f859b0dd3f